These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34621417)

  • 1. QT interval and repolarization dispersion changes during the administration of hydroxychloroquine/chloroquine with/without azithromycin in early COVID 19 pandemic: A prospective observational study from two academic hospitals in Indonesia.
    Gumilang RA; Siswanto ; Anggraeni VY; Trisnawati I; Budiono E; Hartopo AB
    J Arrhythm; 2021 Oct; 37(5):1184-1195. PubMed ID: 34621417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.
    Saint-Gerons DM; Tabarés-Seisdedos R
    Eur J Clin Pharmacol; 2021 Oct; 77(10):1513-1521. PubMed ID: 33938974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course.
    Bakhshaliyev N; Özdemir R
    Ann Noninvasive Electrocardiol; 2021 Jul; 26(4):e12846. PubMed ID: 33956361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.
    Bernardini A; Ciconte G; Negro G; Rondine R; Mecarocci V; Viva T; Santini F; de Innocentiis C; Giannelli L; Witkowska E; Locati ET; Castelvecchio S; Marrocco-Trischitta MM; Vicedomini G; Menicanti L; Pappone C
    Int J Cardiol; 2021 Feb; 324():242-248. PubMed ID: 32956782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
    Sarayani A; Cicali B; Henriksen CH; Brown JD
    Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS).
    Zhao Y; Zhang J; Zheng K; Thai S; Simpson RJ; Kinlaw AC; Xu Y; Wei J; Cui X; Buse JB; Stürmer T; Wang T
    Drugs Real World Outcomes; 2022 Jun; 9(2):231-241. PubMed ID: 35386046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
    O'Connell TF; Bradley CJ; Abbas AE; Williamson BD; Rusia A; Tawney AM; Gaines R; Schott J; Dmitrienko A; Haines DE
    JACC Clin Electrophysiol; 2021 Jan; 7(1):16-25. PubMed ID: 33478708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.
    Bun SS; Taghji P; Courjon J; Squara F; Scarlatti D; Theodore G; Baudouy D; Sartre B; Labbaoui M; Dellamonica J; Doyen D; Marquette CH; Levraut J; Esnault V; Bun SS; Ferrari E
    Clin Pharmacol Ther; 2020 Nov; 108(5):1090-1097. PubMed ID: 32588427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis.
    Agstam S; Yadav A; Kumar-M P; Gupta A
    Indian Pacing Electrophysiol J; 2021; 21(1):36-43. PubMed ID: 33075484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19.
    Özdemir İH; Özlek B; Özen MB; Gündüz R; Çetin N; Bilge AR
    Int J Clin Pract; 2021 Feb; 75(2):e13896. PubMed ID: 33280207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19.
    Gunay S; Caliskan S; Sigirli D; Sahin E
    Bratisl Lek Listy; 2020; 121(11):817-821. PubMed ID: 33164544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of electrocardiographic ventricular repolarization variables in patients with newly diagnosed COVID-19.
    Yenerçağ M; Arslan U; Doğduş M; Günal Ö; Öztürk ÇE; Aksan G; Erdoğan G; Gül S; Yontar OC; Şen A
    J Electrocardiol; 2020; 62():5-9. PubMed ID: 32731139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in QTc interval after hydroxychloroquine therapy in patients with COVID-19 infection: a large, retrospective, multicentre cohort study.
    El Kadri M; Al Falasi O; Ahmed R; Al Awadhi A; Altaha Z; Hillis A; Panikkaveetil B; Abdalla S; Ansel Benette H; Almubarak A; Saifuddin M; Alattar Y; Oulhaj A; AlKaabi S
    BMJ Open; 2022 Feb; 12(2):e051579. PubMed ID: 35140148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.
    Shah RR
    J Clin Pharm Ther; 2021 Feb; 46(1):17-27. PubMed ID: 32981089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients.
    Bakhshaliyev N; Uluganyan M; Enhos A; Karacop E; Ozdemir R
    J Electrocardiol; 2020; 62():59-64. PubMed ID: 32827987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of ECG testing and characteristics among new hydroxychloroquine and chloroquine users within a multi-center tertiary care center.
    Choi MY; Weber B; Stevens E; Guan H; Ellrodt J; Oakes E; Di Carli M; Tedrow U; Sauer W; Costenbader KH
    Rheumatol Int; 2022 Oct; 42(10):1767-1774. PubMed ID: 35430712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hydroxychloroquine treatment on QT interval.
    Hooks M; Bart B; Vardeny O; Westanmo A; Adabag S
    Heart Rhythm; 2020 Nov; 17(11):1930-1935. PubMed ID: 32610165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19.
    Afsin A; Ecemis K; Asoglu R
    J Clin Med Res; 2020 Sep; 12(9):604-611. PubMed ID: 32849949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
    Singh B; Ryan H; Kredo T; Chaplin M; Fletcher T
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013587. PubMed ID: 33624299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
    Mercuro NJ; Yen CF; Shim DJ; Maher TR; McCoy CM; Zimetbaum PJ; Gold HS
    JAMA Cardiol; 2020 Sep; 5(9):1036-1041. PubMed ID: 32936252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.